Stifel Nicolaus initiated coverage on shares of Contineum Therapeutics (NASDAQ:CTNM – Free Report) in a report released on Tuesday, Marketbeat.com reports. The brokerage issued a buy rating and a $29.00 price target on the stock.
Contineum Therapeutics Price Performance
Shares of Contineum Therapeutics stock opened at $14.09 on Tuesday. Contineum Therapeutics has a 1 year low of $13.65 and a 1 year high of $16.06.
Contineum Therapeutics Company Profile
See Also
- Five stocks we like better than Contineum Therapeutics
- The “How” and “Why” of Investing in 5G Stocks
- Appleās Earnings Show Investors Its Strength and Its Weakness
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Bargain Alert: 3 Large Caps With Extremely Oversold RSIs
- How Can Investors Benefit From After-Hours Trading
- DraftKings Q1: Strong Customer Acquisition and Product Innovation
Receive News & Ratings for Contineum Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Contineum Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.